Prophylaxis of thromboembolism in bariatric surgery with parnaparin

Obesity Surgery

Volumn 17, Issue 12, 2007, Pages 1558-1562

  Forestieri, Pietro ^a   Quarto, Gennaro ^a   De Caterina, Maurizio ^a   Cuocolo, Alberto ^a   Pilone, Vincenzo ^a   Formato, Antonio ^a   Ruocco, Aldo ^a   Ferrari, Patrizio ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Medical Service   (Italy)

Author keywords

Bariatric surgery; Low molecular weight heparin; Obesity; Parnaparin; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A; LOW MOLECULAR WEIGHT HEPARIN; PARNAPARIN; PROTHROMBIN A; PROTHROMBIN ANTIBODY;

ADULT; ARTICLE; BARIATRIC SURGERY; BLOOD CLOTTING; BODY MASS; BYPASS SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG DOSE INCREASE; FEMALE; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LUNG SCINTISCANNING; MALE; OBESITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SCINTIPHLEBOGRAPHY; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; BARIATRIC SURGERY; BLOOD COAGULATION TESTS; BODY MASS INDEX; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERMITTENT PNEUMATIC COMPRESSION DEVICES; MALE; MIDDLE AGED; OBESITY, MORBID; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; PULMONARY EMBOLISM; STOCKINGS, COMPRESSION; VENOUS THROMBOEMBOLISM;

EID: 37549048031     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11695-007-9259-z     Document Type: Article

References (25)

1. Karmali S, Shaffer E. The battle against the obesity epidemic: is bariatric surgery the perfect weapon? Clin Invest Med 2005;28:147-56.
2. Virji A, Murr MM. Caring for patients after bariatric surgery. Am Fam Phys 2006;73:1403-8.
3. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002;12:19-24.
4. Newall G, Ruiz-Razura A, Mentz HA, et al. A retrospective study on the use of a low-molecular-weight heparin for thromboembolism prophylaxis in large-volume liposuction and body contouring procedures. Aesthet Plast Surg 2006;30:86-95.
5. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 2005;15:1368-74.
6. Green B, Duffull SB. Development of a dosing strategy for exoxaparin in obese patients. Br J Clin Pharmacol 2003;56:96-103.
7. Kucher N, Leizorovicz A, Vaitkus PT, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients. Arch Intern Med 2005;165:341-5.
8. Kalfarentzos F, Stavropoulou F, Yarmenitis S, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg 2001;11:670-6.
9. Sanderink G-J, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72:308-18.
10. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. Eur J Clin Pharmacol 2000;56:293-7.
11. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002;87:817-23.
12. Mousa SA, Johansen K. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide. Int Angiol 2005;24:40-42.
13. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002;12:19-24.
14. Frampton JE, Faulds D. Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs 1994;47:652-76.
15. PRIME CARE Study Investigators Group. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study. Indian Heart J 2005;57:648-54.
16. Hoppensteadt D. Clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Haematologica 2005;90:727B.
17. Favaloro EJ, Bonar R, Aboud M, on behalf of the RCPA QAP in Haematology. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Lab Hematol 2005;11:157-62.
18. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:188S-203S.
19. Gyamfi C, Cohen R, Desancho MT, et al. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels. J Matern-Fetal Neonatal Med 2005;18:329-31.
20. Sarig G, Blumenfeld Z, Leiba R, et al. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 2005;94:980-5.
21. O'Connell MP, O'Leary M, MacKeogh L, et al. Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis? Eur J Obstet Gynecol Reprod Biol 2004;114:12-4.
22. Rutherford EJ, Schooler WG, Sredzienski E, et al. Optimal dose of enoxaparin in critically ill trauma and surgical patients. J Trauma 2005;58:1167-70.
23. Wilson SJ, Wilbur K, Burton E, et al. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001;31:42-8.
24. Smith J, Canton EM. Weight-based administration of dalteparin in obese patients. Am J Health Syst Pharm 2003;60:683-7.
25. Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-7.